Statera Biopharma, Inc.

$0.00+0.00%(+$0.00)
TickerSpark Score
41/100
Weak
80
Valuation
40
Profitability
15
Growth
40
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STAB research report →

52-Week Range0% of range
Low $0.00
Current $0.00
High $0.03

Companywww.staterabiopharma.com

Statera BioPharma, Inc. , a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers.

CEO
Blake Hawley
IPO
2021
Employees
46
HQ
Fort Collins, CO, US

Price Chart

+0.00% · this period
$0.03$0.01$0.00May 20Nov 18May 20

Valuation

Market Cap
$7.14K
P/E
-0.00
P/S
0.00
P/B
-0.00
EV/EBITDA
-0.08
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
6677.48%
ROIC
-666.54%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$-174,408,164 · -1218.82%
EPS
$-4.97 · -855.77%
Op Income
$-98,343,803
FCF YoY
-457.30%

Performance & Tape

52W High
$0.03
52W Low
$0.00
50D MA
$0.00
200D MA
$0.00
Beta
-4.78
Avg Volume
6.28K

Get TickerSpark's AI analysis on STAB

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Feb 22, 22Chandrasekhar Satishchandranother0
Sep 9, 21SALUCK RANDY S.other60,000
Sep 9, 21Barbarick Steve Kother60,000
Sep 9, 21Verny Leaother60,000
Sep 28, 21Markvicka Tauniaother100,000
Jul 27, 21Handley Michael Kother296,609
Jul 27, 21Handley Michael Kother0
Jul 27, 21Buckheit Robertother24,378
Jul 27, 21Selsky Cliffordother101,579
Jul 27, 21McAvoy Cozette M.other60,947

Our STAB Coverage

We haven't published any research on STAB yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate STAB Report →

Similar Companies